Research programme: cytomegalovirus infections - GPC Biotech
Latest Information Update: 22 Jan 2007
At a glance
- Originator GPC Biotech AG
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 10 Apr 2000 Preclinical development for Cytomegalovirus infections in Germany (Unknown route)